Financial reports
10-K
2023 FY
Annual report
1 Mar 24
ARS
2022 FY
Annual report to shareholders
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
29 Feb 24
8-K
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
3 Jan 24
8-K
Departure of Directors or Certain Officers
13 Dec 23
8-K
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
13 Nov 23
8-K
VYNE Therapeutics Announces Private Placement of $88 Million
30 Oct 23
8-K
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
8-K
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
8-K
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development
1 May 23
8-K
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
9 Mar 23
8-K
Entry into a Material Definitive Agreement
28 Feb 23
Registration and prospectus
S-3
Shelf registration
1 Mar 24
S-8
Registration of securities for employees
1 Mar 24
S-8
Registration of securities for employees
13 Dec 23
424B3
Prospectus supplement
22 Nov 23
D
$88.15 mm in equity / options / securities to be acquired, sold $88.15 mm, 19 investors
16 Nov 23
S-3
Shelf registration
13 Nov 23
D
$300.00 k in equity, sold $300.00 k, 1 investor
18 Nov 22
424B5
Prospectus supplement for primary offering
12 May 22
S-8
Registration of securities for employees
17 Mar 22
424B5
Prospectus supplement for primary offering
15 Mar 22
Proxies
DEF 14A
Definitive proxy
13 Nov 23
DEF 14A
Definitive proxy
25 Nov 22
PRE 14A
Preliminary proxy
14 Nov 22
DEFA14A
Additional proxy soliciting materials
28 Jul 22
DEFA14A
Additional proxy soliciting materials
19 Jul 22
DEFA14A
Additional proxy soliciting materials
7 Jul 22
DEF 14A
Definitive proxy
17 Jun 22
PRE 14A
Preliminary proxy
7 Jun 22
DEFA14A
Additional proxy soliciting materials
29 Jun 21
DEFA14A
Additional proxy soliciting materials
7 Jun 21
Other
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
24 Nov 23
CORRESP
Correspondence with SEC
20 Nov 23
UPLOAD
Letter from SEC
17 Nov 23
EFFECT
Notice of effectiveness
17 May 21
CORRESP
Correspondence with SEC
11 May 21
UPLOAD
Letter from SEC
10 May 21
EFFECT
Notice of effectiveness
8 Jan 20
CORRESP
Correspondence with SEC
6 Jan 20
UPLOAD
Letter from SEC
9 Dec 19